# ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center

> **NCT03608059** · PHASE4 · COMPLETED · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 418 (actual)

## Conditions studied

- Myeloid Tumor

## Interventions

- **DRUG:** ATG/PTCy
- **DRUG:** standard ATG
- **DRUG:** standard PTCy

## Key facts

- **NCT ID:** NCT03608059
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-28
- **Primary completion:** 2023-08-23
- **Final completion:** 2023-08-23
- **Target enrollment:** 418 (ACTUAL)
- **Last updated:** 2023-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03608059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03608059, "ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03608059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*